Erle Mast - Clovis Oncology Insider

CLVS -- USA Stock  

USD 47.87  0.83  1.76%

Mr. Erle T. Mast is no longer Chief Financial Officer Executive Vice President of Clovis Oncology Inc. effective March 31 2016. He is one of the cofounders. Previously Mr. Mast served in the same role at Pharmion Corporationrationration beginning in 2002. From 1997 through 2002 Mr. Mast worked for Dura Pharmaceuticals Inc. and its successor Elan Corporationrationration. From 2000 to 2002 he served as Chief Financial Officer for the Global Biopharmaceuticals business unit for Elan. From 1997 to 2000 Mr. Mast served as Vice President of Finance for Dura Pharmaceuticals. Prior to that Mr. Mast was a partner with Deloitte Touche LLP. Mr. Mast also serves on the board of directors of Zogenix Inc. and Receptos Inc.
Age: 51  Founder Since 2009      
Mast received a B.Sc. in business administration from California State University Bakersfield.

Erle Mast Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (25.72) % which means that it has lost $25.72 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (152.2) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 282.73 M in liabilities with Debt to Equity (D/E) ratio of 92.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clovis Oncology has Current Ratio of 6.42 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 360 people.Clovis Oncology (CLVS) is traded on BATS Exchange in USA. It is located in COLORADO U.S.A and employs 360 people. Clovis Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.

Clovis Oncology Leadership Team

James Blair, Independent Director
James Barrett, Independent Chairman of the Board
Thorlef Spickschen, Independent Director
Brian Atwood, Independent Director
Edward McKinley, Independent Director
Paul Klingenstein, Independent Director
Dale Hooks, Senior Vice President Chief Commercial Officer
MB BSc, Chief Medical Officer and Executive VP of Clinical and Preclinical Devel. and Pharmacovigilance
Keith Flaherty, Director
Lindsey Rolfe, Chief Medical Officer, Executive Vice President - Clinical and Preclinical Development & Pharmacovigilance
Breanna Burkart, Sr. Director of Investor Relations
Steven Hoerter, Chief Commercial Officer and Executive VP
Erle Mast, Co-Founder, CFO, Executive VP and Secretary
Patrick Mahaffy, President CEO, Director
Ginger Graham, Independent Director
Gillian IversRead, Executive Vice President - Technical Operations, Chief Regulatory Officer
Michael Barrett, Independent Chairman of the Board
Daniel Muehl, Principal Financial Officer, Principal Accounting Officer

Stock Performance Indicators

Current Sentiment - CLVS

Clovis Oncology Investor Sentiment
Most of Macroaxis users are currently bullish on Clovis Oncology. What is your opinion about investing in Clovis Oncology? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Clovis Oncology and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.